title: Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.
abstract: Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from 122.8 ± 6.7 to 133.3 ± 8.3 mEq/l, and symptoms due to hyponatremia were improved. On the basis of these results, mozavaptan (Physuline(®)) was approved as an orphan drug for the treatment of the syndrome in 2006 in Japan. During the 43 months following its launch, 100 patients have been treated with the drug; overall clinical effects of the drug were found similar to those of this clinical trial. Clinically, mozavaptan may allow hyponatremic patients to be treated by aggressive cancer chemotherapy with platinum-containing drugs. Moreover, the drug may free patients from strict fluid-intake restrictions and thereby improve their quality of life.
authors.affiliation: Office of the President, Shizuoka Cancer Center, Sunto-gun, Shizuoka 411-8777, Japan. k.yamaguchi@scchr.jp
authors.forename: Ken
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Noriharu
authors.initials: N
authors.lastname: Shijubo
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kodama
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Mori
authors.forename: Takahiko
authors.initials: T
authors.lastname: Sugiura
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kuriyama
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Tetsu
authors.initials: T
authors.lastname: Shinkai
authors.forename: Haruo
authors.initials: H
authors.lastname: Iguchi
authors.forename: Masanori
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D000368:Aged; D065092:Antidiuretic Hormone Receptor Antagonists; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018288:Carcinoma, Small Cell / Q000150:complications; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D011788:Quality of Life; D012964:Sodium / Q000097:blood; D013953:Thymus Neoplasms / Q000150:complications; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000150:complications
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D000970:Antineoplastic Agents; D001549:Benzamides; D001552:Benzazepines; D015415:Biomarkers; C076251:mozavaptan; D012964:Sodium